Literature DB >> 29623408

[Thromboembolism prophylaxis in old age].

Gabriele Röhrig1, Gerald Kolb2.   

Abstract

Anticoagulation in geriatric patients is challenging regarding the risk of bleeding complications and thromboembolic problems. Age, comorbidities, such as renal insufficiency and polymedication have a vital impact on bleeding and thromboembolic risks; however, age is not an exclusion criterion for withholding anticoagulation. Age is the main risk factor for deep vein thrombosis and atrial fibrillation becomes more relevant with aging. Older patients with atrial fibrillation have a particularly high risk of having a stroke. Therefore, very old patients benefit particularly from oral anticoagulation because the risk of bleeding is outweighed by the clinical benefit of stroke prevention. Risk of bleeding and thromboembolic problems can be easily assessed by established diagnostic tools. This article reviews the epidemiology of thromboembolic problems in the aged as well as current diagnostic and therapeutic steps for primary and secondary prevention.

Entities:  

Keywords:  Anticoagulants; Atrial fibrillation; Bleeding; Deep-vein thrombosis; Embolisms

Mesh:

Substances:

Year:  2018        PMID: 29623408     DOI: 10.1007/s00391-018-1384-x

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  51 in total

1.  Cerebral vascular accidents in patients over the age of 60. II. Prognosis.

Authors:  J RANKIN
Journal:  Scott Med J       Date:  1957-05       Impact factor: 0.729

2.  The Timed Test of Money Counting: a short physical performance test for manual dexterity and cognitive capacity.

Authors:  T Nikolaus; M Bach; N Specht-Leible; P Oster; G Schlierf
Journal:  Age Ageing       Date:  1995-05       Impact factor: 10.668

Review 3.  Management of thrombosis in cancer: primary prevention and secondary prophylaxis.

Authors:  Agnes Y Y Lee
Journal:  Br J Haematol       Date:  2005-02       Impact factor: 6.998

4.  Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients.

Authors:  Gerald Kolb; Iris Bodamer; Heide Galster; Christoph Seidlmayer; Konrad Grambach; Karel Koudela; Ralf R Eisele; Clemens Becker; Valerie Paal; Uwe Spannagel; Joachim Brom; Gottfried Weidinger
Journal:  Thromb Haemost       Date:  2003-12       Impact factor: 5.249

5.  Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial.

Authors:  A Piccioli; A W A Lensing; M H Prins; A Falanga; G L Scannapieco; M Ieran; M Cigolini; G B Ambrosio; M Monreal; A Girolami; P Prandoni
Journal:  J Thromb Haemost       Date:  2004-06       Impact factor: 5.824

Review 6.  Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism?

Authors:  Marc Carrier; Grégoire Le Gal; Philip S Wells; Dean Fergusson; Tim Ramsay; Marc A Rodger
Journal:  Ann Intern Med       Date:  2008-09-02       Impact factor: 25.391

Review 7.  Status of the epidemiology of atrial fibrillation.

Authors:  William B Kannel; Emelia J Benjamin
Journal:  Med Clin North Am       Date:  2008-01       Impact factor: 5.456

8.  The diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein thrombosis.

Authors:  Paolo Prandoni; Anthonie W A Lensing; Enrico Bernardi; Sabina Villalta; Paola Bagatella; Antonio Girolami
Journal:  Thromb Haemost       Date:  2002-09       Impact factor: 5.249

Review 9.  Optimal Stroke Prevention in the Geriatric Patient with Atrial Fibrillation: Position Paper of an Interdisciplinary Expert Panel.

Authors:  P Bahrmann; M Wehling; D Ropers; J Flohr; A Leischker; J Röther
Journal:  Drug Res (Stuttg)       Date:  2014-10-06

10.  CHADS2 score has a better predictive value than CHA2DS2-VASc score in elderly patients with atrial fibrillation.

Authors:  Yunli Xing; Qing Ma; Xiaoying Ma; Cuiying Wang; Dai Zhang; Ying Sun
Journal:  Clin Interv Aging       Date:  2016-07-14       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.